This is the authors' abstract. We don't add key points for this paper.
The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. In addition, the combination results in no apparent increase in toxicity. Finally, the pharmacology of rhuMAb HER2 was unaffected by coadministration with CDDP.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Pegram et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: